Advertisement

Topics

Mylan, embattled maker of EpiPen, faces a crucial test as angry investors plot to oust CEO

04:30 EDT 21 Jun 2017 | STAT

Battered by the EpiPen pricing scandal, government probes and outrage over executive compensation, Mylan directors face a reckoning.

Original Article: Mylan, embattled maker of EpiPen, faces a crucial test as angry investors plot to oust CEO

NEXT ARTICLE

More From BioPortfolio on "Mylan, embattled maker of EpiPen, faces a crucial test as angry investors plot to oust CEO"

Advertisement
Quick Search
Advertisement
Advertisement